The news was announced at the American Stroke Association's International Stroke Conference earlier this month. Research suggests that NimoGel effectively prevented cerebral vasospasm, which is the constriction of blood vessels in the brain, after subarachnoid hemorrhage (SAH). Cerebral vasospasm is a leading cause of permanent brain damage and death after brain injury.
"There is a tremendous unmet medical need in treating brain injuries. Treatments available today are only minimally effective in part because the systemically administered doses that can be tolerated by patients are too low to prevent certain types of delayed complications such as cerebral vasospasm," said R. Loch Macdonald, MD, PhD, Keenan Endowed Chair and Head of the Division of Neurosurgery at St. Michael's Hospital, University of Toronto and Chief Scientific Officer of Edge Therapeutics.
"This preclinical study suggests that it is possible to achieve adequate and sustained concentrations of nimodipine locally and prevent cerebral vasospasm and other potentially deadly complications after brain injury. Based on these encouraging results in a large animal model, further evaluation of NimoGel in human clinical trials is warranted."
Have you or someone you love suffered a serious injury or a traumatic brain injury as the result of an accident in Kansas or Missouri? If so, you may be entitled to compensation for your losses. Contact experienced Kansas City Personal Injury Lawyer James Roswold. With over 15 years of experience in Brain and Spinal Injuries including cases of TBI, we may be able to help you and your family determine the best way to proceed with your personal injury claim.
Contact Kansas City Accident Injury Attorneys to set up a free consultation to discuss your case. You can get started today by downloading our free book, "10 Essential Steps to Protecting Your Injury Claim". We want you to know your rights.
